DrugPatentWatch Database Preview
Aerie Pharms Inc Company Profile
What is the competitive landscape for AERIE PHARMS INC, and what generic alternatives to AERIE PHARMS INC drugs are available?
There are five US patents protecting AERIE PHARMS INC drugs.
There are thirty-four patent family members on AERIE PHARMS INC drugs in seven countries.
Summary for Aerie Pharms Inc
| International Patents: | 34 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Aerie Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aerie Pharms Inc | RHOPRESSA | netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208254-001 | Dec 18, 2017 | RX | Yes | Yes | 9,415,043 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Aerie Pharms Inc | RHOPRESSA | netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208254-001 | Dec 18, 2017 | RX | Yes | Yes | 8,394,826 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Aerie Pharms Inc | RHOPRESSA | netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208254-001 | Dec 18, 2017 | RX | Yes | Yes | 8,450,344 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Aerie Pharms Inc | RHOPRESSA | netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208254-001 | Dec 18, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Aerie Pharms Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,512,101 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | ➤ Sign Up |
| 8,716,310 | Dual mechanism inhibitors for the treatment of disease | ➤ Sign Up |
| 9,849,122 | Combination therapy | ➤ Sign Up |
| 8,759,388 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Aerie Pharms Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2424857 | ➤ Sign Up |
| Canada | 2929545 | ➤ Sign Up |
| Australia | 2017248440 | ➤ Sign Up |
| European Patent Office | 3053913 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
